Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2018

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal first quarter ended December 31, 2018.

Enantas research and development programs are progressing well and we have many clinical goals that we expect to achieve this year, said Jay R. Luly, Ph.D. President and CEO, Enanta Pharmaceuticals. By mid-year, we expect to announce top-line data from our Phase 2a human challenge study of EDP-938 for RSV, followed by Phase 2a data from our NASH study. We also expect to initiate a Phase 1 study with our new HBV core inhibitor candidate EDP-514 in the second half of 2019.

Fiscal First Quarter Ended December 31, 2018 Financial Results

Total revenue for the three months ended December 31, 2018 was $69.9 million and consisted entirely of royalty revenue from worldwide net sales of AbbVies hepatitis C virus (HCV) regimens MAVYRET„¢/MAVIRET„¢, as well as its HCV regimens containing paritaprevir. For the three months ended December 31, 2017, total revenue was $38.1 million which consisted of a $15.0 million milestone payment for the reimbursement approval of MAVIRET„¢ in Japan and royalty revenue primarily earned on AbbVies global net sales from the launch of MAVYRET„¢/MAVIRET„¢ in major markets in the second half of 2017.

Research and development expenses totaled $34.9 million for the three months ended December 31, 2018, compared to $18.0 million for the three months ended December 31, 2017. The increase in research and development expenses was primarily due to increased preclinical and clinical costs associated with the progression of Enantas wholly-owned R&D programs in respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC), as well as research efforts in hepatitis B virus (HBV).

General and administrative expenses totaled $7.2 million for the three months ended December 31, 2018, compared to $5.8 million for the three months ended December 31, 2017. The increase in general and administrative expenses was primarily due to increases in compensation expense driven by increased headcount.

Enanta recorded income tax expense of $3.7 million for the three months ended December 31, 2018 compared to an income tax expense of $3.6 million for the same period in 2017. Enantas effective tax rate for the December 31, 2018 quarter was approximately 13%.

Net income for the three months ended December 31, 2018 was $26.0 million, or $1.25 per diluted common share, compared to net income of $11.7 million, or $0.59 per diluted common share, for the corresponding period in 2017.

Enantas cash, cash equivalents and short-term and long-term marketable securities totaled $357.3 million at December 31, 2018. This compares to a total of $325.1 million at September 30, 2018. Enanta expects that its current cash, cash equivalents and marketable securities, as well as its continuing royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs for the foreseeable future.

Development Programs and Business Review

EDP-938, N-Protein Inhibitor for Respiratory Syncytial Virus:

  • Dosing is ongoing in a Phase 2a human challenge study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of EDP-938 orally administered to healthy subjects infected with a strain of respiratory syncytial virus. The trial is advancing well, and topline data is now expected mid-2019.

EDP-514, Core Inhibitor for Hepatitis B Virus:

  • In January, Enanta announced positive preclinical data on EDP-514, a promising inhibitor of the HBV core protein. Data demonstrated potent inhibition of HBV replication in vitro accompanied by a greater than 4-log viral load reduction in a humanized liver mouse model after 12 weeks of dosing.
  • A Phase 1 study of EDP-514, is planned to begin in the second half of 2019. The study will evaluate single and multiple doses of drug in healthy volunteers and will incorporate a Phase 1b arm in patients with chronic HBV infection.

EDP-305, FXR agonist for NASH:

  • Enrollment in the 12-week Phase 2a NASH trial is expected to conclude in the first quarter of 2019, allowing Enanta to report preliminary top line data in the third quarter of calendar 2019.
  • Enanta also expects to identify a follow-on FXR clinical candidate in calendar 2019.

Upcoming Events and Presentations

  • 31st Annual Roth Conference, March 17-19, 2019, Dana Point, CA
  • Oppenheimers 29th Annual Healthcare Conference, March 19-20, 2019, New York
  • Preclinical data presentations from our NASH and HBV programs at The International Liver Congress, Vienna, Austria, April 10-14, 2019
  • Enanta plans to issue its fiscal second quarter financial results press release, and hold a conference call regarding those results, on May 7, 2019.

Conference Call and Webcast Information Enanta will host a conference call and webcast today at 4:30 p.m. ET. To participate in the live conference call, please dial (855) 840-0595 in the U.S. or (518) 444-4814 for international callers. A replay of the conference call will be available starting at approximately 7:30 p.m. ET on February 6, 2019, through 11:59 p.m. ET on February 8, 2019 by dialing (855) 859-2056 from the U.S. or (404) 537-3406 for international callers. The passcode for both the live call and the replay is 1190228. A live audio webcast of the call and replay can be accessed by visiting the Events and Presentation section on the Investors page of Enantas website at www.enanta.com.

About Enanta Pharmaceuticals, Inc. Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enantas research and development efforts are currently focused on the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), and hepatitis B virus (HBV).

Enantas research and development activities are currently funded by royalties from HCV products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is now sold by AbbVie in numerous countries as part of its newest treatment for chronic hepatitis C virus (HCV) infection. This leading HCV regimen is sold under the tradenames MAVYRET„¢ (U.S.) and MAVIRET„¢ (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

FORWARD LOOKING STATEMENTS This press release contains forward-looking statements, including statements with respect to the prospects for advancement of Enantas clinical programs in RSV and NASH/PBC and its preclinical program in HBV, as well as the prospects for future royalty revenue to Enanta from sales of AbbVies MAVYRET„¢/MAVIRET„¢ regimen for HCV. Statements that are not historical facts are based on managements current expectations, estimates, forecasts and projections about Enantas business and the industry in which it operates and managements beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: Enantas revenues in the short-term are dependent upon the continued success of AbbVies commercialization of its MAVYRET„¢/MAVIRET„¢ HCV regimen; the impact of development, regulatory and marketing efforts of others with respect to competitive treatments for RSV, NASH, PBC and HBV; competitive pricing, market acceptance and reimbursement rate actions affecting MAVYRET„¢/MAVIRET„¢ compared to competitive HCV products on the market; the discovery and development risks of Enantas programs in RSV, NASH, PBC, and HBV; the competitive impact of development, regulatory and marketing efforts of others in those disease areas; Enantas lack of clinical development experience; Enantas need to attract and retain senior management and key research and development personnel; Enantas need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in Risk Factors in Enantas most recent Form 10-K for the fiscal year ended September 30, 2018, and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.

 
ENANTA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED (in thousands, except per share amounts)
                 
 
Three Months Ended December 31,
2018 2017
 
Revenue $ 69,886 $ 38,109
Operating expenses
Research and development 34,878 17,962
General and administrative   7,152     5,770  
Total operating expenses   42,030     23,732  
Income from operations 27,856 14,377
Other income, net   1,885     960  
Income before income taxes 29,741 15,337
Income tax expense   (3,730 )   (3,644 )
Net income $ 26,011   $ 11,693  
 
 
Net income per share
Basic $ 1.34 $ 0.61
Diluted $ 1.25 $ 0.59
Weighted average common shares outstanding
Basic 19,426 19,130
Diluted 20,810 19,918
 
 

ENANTA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS UNAUDITED (in thousands)

               
December 31, 2018 September 30, 2018
Assets
Current assets
Cash and cash equivalents $ 74,365 $ 63,902
Short-term marketable securities 271,423 244,828
Accounts receivable 69,886 67,205
Prepaid expenses and other current assets   7,636   4,454
Total current assets 423,310 380,389
Long-term marketable securities 11,465 16,389
Property and equipment, net 9,493 8,374
Deferred tax assets 9,248 8,375
Restricted cash 608 608
Other long-term assets   92   92
Total assets $ 454,216 $ 414,227
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable $ 5,622 $ 4,745
Accrued expenses and other current liabilities 11,152 9,892
Income taxes payable   5,858   1,388
Total current liabilities 22,632 16,025
Series 1 nonconvertible preferred stock 1,628 1,628
Other long-term liabilities   3,121   2,895
Total liabilities   27,381   20,548
Total stockholders’ equity   426,835   393,679
Total liabilities and stockholders’ equity $ 454,216 $ 414,227

Investor Contact:
Carol Miceli
617-607-0710
[email protected]

Media
Contact:
Kari Watson
MacDougall Biomedical Communications
781-235-3060
[email protected]